Verici Dx plc announced that it has signed an exclusive global licensing agreement with Thermo Fisher Scientific, the world leader in serving science, to further develop an assay for pre-transplantprognostic testing for risk of early kidney rejection. The exclusive license grants Thermo Fisher the rights to develop an assay for pre-transplant risk assessment for further development as a Laboratory Developed Test (LDT) in its CLIA laboratory in the U.S., as well as the sole right, but not obligation, to manufacture, distribute and sell the assay worldwide. The license agreement includes an upfront payment to the Company, along with a number of further payments conditional upon operational deliverables related to technology transfer and related publications.

In addition, Verici Dx has granted Thermo Fisher a non-exclusive license for access to a portion of the Company's urine samples, demonstrating the additional value in the Company's data and sample assets for research. Under the above arrangements, payment events for Verici Dx over the next 12 months are expected to total approximately $5 million with a further payment thereafter, in addition to ongoing royalties on tests sold.